PDE11A Antikörper (C-Term)
-
- Target Alle PDE11A Antikörper anzeigen
- PDE11A (phosphodiesterase 11A (PDE11A))
-
Bindungsspezifität
- AA 420-480, C-Term
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser PDE11A Antikörper ist unkonjugiert
-
Applikation
- ELISA, Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Immunocytochemistry (ICC), Confocal Microscopy (CM)
- Aufreinigung
- Affinity Purified
- Immunogen
- Synthetic peptide taken within amino acid region 420-480 on PDE11A protein, common to all PDE11A variants.
- Isotyp
- IgG
- Top Product
- Discover our top product PDE11A Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.69 μg/μL
-
-
Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?" in: Current pharmaceutical design, Vol. 21, Issue 3, pp. 389-416, (2015) (PubMed).
: "Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain." in: Cellular signalling, Vol. 26, Issue 2, pp. 383-97, (2014) (PubMed).
: "Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer." in: World journal of urology, Vol. 31, Issue 2, pp. 325-30, (2013) (PubMed).
: "cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle." in: American journal of physiology. Endocrinology and metabolism, Vol. 301, Issue 2, pp. E342-50, (2011) (PubMed).
: "PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system." in: Brain research, Vol. 1281, pp. 25-34, (2009) (PubMed).
: "Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation." in: Molecular reproduction and development, Vol. 71, Issue 4, pp. 495-508, (2006) (PubMed).
: "Expression of PDE11A in normal and malignant human tissues." in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 53, Issue 7, pp. 895-903, (2005) (PubMed).
: "
-
Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?" in: Current pharmaceutical design, Vol. 21, Issue 3, pp. 389-416, (2015) (PubMed).
-
- Target
- PDE11A (phosphodiesterase 11A (PDE11A))
- Andere Bezeichnung
- PDE11A (PDE11A Produkte)
- Synonyme
- PPNAD2 antikoerper, 6330414F14Rik antikoerper, A630086N24Rik antikoerper, Gm350 antikoerper, PDE11A1 antikoerper, si:ch211-222f23.5 antikoerper, PDE11A antikoerper, ppnad2 antikoerper, Pde11a antikoerper, phosphodiesterase 11A antikoerper, phosphodiesterase 11a antikoerper, dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A antikoerper, PDE11A antikoerper, Pde11a antikoerper, pde11a antikoerper, LOC100470038 antikoerper
- UniProt
- Q9HCR9
- Pathways
- cAMP Metabolic Process
-